Bridgewater Associates Lp decreased its stake in Open Text Corp (OTEX) by 23.98% based on its latest 2019Q1 regulatory filing with the SEC. Bridgewater Associates Lp sold 20,028 shares as the company’s stock rose 10.90% . The hedge fund held 63,508 shares of the edp services company at the end of 2019Q1, valued at $2.44M, down from 83,536 at the end of the previous reported quarter. Bridgewater Associates Lp who had been investing in Open Text Corp for a number of months, seems to be less bullish one the $11.20 billion market cap company. The stock increased 2.98% or $1.2 during the last trading session, reaching $41.53. About 1.06 million shares traded or 57.65% up from the average. Open Text Corporation (NASDAQ:OTEX) has risen 15.34% since September 5, 2018 and is uptrending. It has outperformed by 15.34% the S&P500. Some Historical OTEX News: 09/05/2018 – OPEN TEXT 3Q ADJ EPS 54C, EST. 62C; 02/04/2018 MADHU RANGANATHAN JOINS OPENTEXT AS CHIEF FINANCIAL OFFICER; 09/05/2018 – Open Text 3Q EPS 22c; 09/05/2018 – OPEN TEXT 3Q REV. $686M, EST. $691.8M; 18/05/2018 – Document Management Software 2018: Global Procurement Market Intelligence Report – Top Five Players are Adobe, OpenText, Dropbox, HP, and Oracle – ResearchAndMarkets.com; 17/04/2018 – Hedge fund manager Cliff Robbins reveals investment in software company Open Text; 09/05/2018 – OPENTEXT BOOSTS QTR DIV BY 15%; 09/05/2018 – OPENTEXT BOOSTS QTR DIV TO 15.18C/SHR FROM 13.2C, EST. 15.5C; 02/04/2018 – Open Text Names Madhu Ranganathan CFO; 15/05/2018 – OpenText to Bring Security to the Edges of the Network and Beyond
Cliftonlarsonallen Wealth Advisors Llc decreased its stake in Merck & Co Inc (MRK) by 42.4% based on its latest 2019Q1 regulatory filing with the SEC. Cliftonlarsonallen Wealth Advisors Llc sold 13,421 shares as the company’s stock rose 5.42% . The institutional investor held 18,231 shares of the health care company at the end of 2019Q1, valued at $1.52 million, down from 31,652 at the end of the previous reported quarter. Cliftonlarsonallen Wealth Advisors Llc who had been investing in Merck & Co Inc for a number of months, seems to be less bullish one the $220.42B market cap company. The stock increased 0.05% or $0.04 during the last trading session, reaching $86.09. About 6.17M shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 28.05% since September 5, 2018 and is uptrending. It has outperformed by 28.05% the S&P500. Some Historical MRK News: 07/03/2018 – MERCK – TO PAY EISAI UPFRONT PAYMENT OF $300 MLN U.S. DOLLARS AND UP TO $650 MILLION U.S. DOLLARS FOR CERTAIN OPTION RIGHTS THROUGH 2020 AS PER DEAL; 26/03/2018 – Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma; 06/04/2018 – Incyte knocked as combo drug trial with Merck fails; 12/03/2018 – ADXS, $AZN.GB: $ADXS Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab) – ! $AZN.GB $ADXS; 15/05/2018 – MERCK KGAA MRCG.DE SAYS CONTINUES TO EXPECT FOR THE FULL YEAR 2018 A MODERATE ORGANIC NET SALES INCREASE OF BETWEEN 3% AND 5% OVER THE PREVIOUS YEAR; 16/04/2018 – BRISTOL-MYERS SQUIBB CO – THERE WERE NO STATISTICALLY SIGNIFICANT DIFFERENCES BETWEEN 2 ARMS FOR PFS FOR OPDIVO & INVESTIGATOR’S CHOICE, RESPECTIVELY; 06/04/2018 – IGNORE: MERCK KGAA EVOBRUTINIB STUDY RESULTS REPORTED MAR. 7; 27/03/2018 – ADVISORY-Alerts on Merck & Co’s fast-track designation for tepotinib withdrawn; 08/05/2018 – NEON THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN CLINICAL TRIAL EVALUATING PERSONAL CANCER VACCINE NEO-PV-01 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) AND CHEMOTHERAPY; 10/04/2018 – Oncolytics Biotech: Combination Therapy With REOLYSIN(R), Keytruda(R) and/or anti-CD73 Immunotherapy Led to Rejection of Pre-Established Tumors
Analysts await Open Text Corporation (NASDAQ:OTEX) to report earnings on October, 30. They expect $0.32 earnings per share, up 146.15% or $0.19 from last year’s $0.13 per share. OTEX’s profit will be $86.28M for 32.45 P/E if the $0.32 EPS becomes a reality. After $0.27 actual earnings per share reported by Open Text Corporation for the previous quarter, Wall Street now forecasts 18.52% EPS growth.
More notable recent Open Text Corporation (NASDAQ:OTEX) news were published by: Fool.ca which released: “This 1 Stock Is All You Need to Retire Wealthy – The Motley Fool Canada” on August 07, 2019, also Nasdaq.com with their article: “Open Text Corporation (OTEX) Ex-Dividend Date Scheduled for May 30, 2019 – Nasdaq” published on May 29, 2019, Nasdaq.com published: “RSI Alert: Open Text Now Oversold – Nasdaq” on August 02, 2019. More interesting news about Open Text Corporation (NASDAQ:OTEX) were released by: Nasdaq.com and their article: “Open Text (OTEX) Soars to 52-Week High, Time to Cash Out? – Nasdaq” published on June 10, 2019 as well as Nasdaq.com‘s news article titled: “Open Text Corporation (OTEX) Ex-Dividend Date Scheduled for August 29, 2019 – Nasdaq” with publication date: August 28, 2019.
Bridgewater Associates Lp, which manages about $16.33 billion US Long portfolio, upped its stake in Signature Bk New York N Y (NASDAQ:SBNY) by 23,115 shares to 28,981 shares, valued at $3.71M in 2019Q1, according to the filing. It also increased its holding in Ishares Tr (EMB) by 88,073 shares in the quarter, for a total of 1.85 million shares, and has risen its stake in Anadarko Pete Corp (NYSE:APC).
More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Forbes.com which released: “How Important Is Keytruda For Merck? – Forbes” on August 29, 2019, also Streetinsider.com with their article: “Merck (MRK) announces EC Approves its KEYTRUDA in Combination with Inlyta as First-Line Treatment for Patients with Advanced RCC – StreetInsider.com” published on September 04, 2019, Seekingalpha.com published: “HHS pledges $23M for Merck’s Ebola vaccine – Seeking Alpha” on August 22, 2019. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Seekingalpha.com and their article: “Leerink likes Merck in premarket analyst action – Seeking Alpha” published on August 16, 2019 as well as Fool.com‘s news article titled: “Why Jim Cramer’s Negative Take on Pfizer Is Flat-Out Wrong – The Motley Fool” with publication date: August 27, 2019.
Investors sentiment decreased to 0.81 in Q1 2019. Its down 0.11, from 0.92 in 2018Q4. It worsened, as 50 investors sold MRK shares while 702 reduced holdings. 141 funds opened positions while 468 raised stakes. 1.86 billion shares or 4.24% less from 1.94 billion shares in 2018Q4 were reported. Wealthquest Corp has invested 0.78% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Westpac Banking holds 355,845 shares or 0% of its portfolio. Archford Capital Strategies Limited Liability Co reported 8,350 shares stake. Moreover, Mcmillion Mgmt Inc has 1.86% invested in Merck & Co., Inc. (NYSE:MRK). 1St Source State Bank has 120,312 shares. Pnc Fin Svcs Group has invested 0.73% in Merck & Co., Inc. (NYSE:MRK). Royal Comml Bank Of Canada reported 0.46% stake. Prudential Public Limited Liability Co reported 0.67% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Stifel Financial has 4.42M shares for 1.04% of their portfolio. Cornerstone Capital holds 0.09% or 6,841 shares in its portfolio. 6,452 were reported by Spectrum Gp. National Bank Of America Corporation De reported 42.43M shares or 0.55% of all its holdings. Whittier invested 0.73% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Centurylink Mngmt reported 39,093 shares. Inverness Counsel Llc New York accumulated 0.13% or 27,884 shares.
Cliftonlarsonallen Wealth Advisors Llc, which manages about $2.03B and $914.42M US Long portfolio, upped its stake in Ishares Tr (FLOT) by 136,080 shares to 356,632 shares, valued at $18.16 million in 2019Q1, according to the filing. It also increased its holding in Ishares Tr by 31,201 shares in the quarter, for a total of 132,476 shares, and has risen its stake in Ishares Tr (GOVT).
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.